14th Annual Indy

Hematology Review

SATURDAY, MARCH 11, 20177:00 AM – 6:00 PM

Indianapolis Marriott Downtown350 W. Maryland Street

Indianapolis, IN

A full day of presentati ons by today’s leaders in hematology and hematologic malignancies

You are invited to Indianapolis for a full day of presentati ons by the nati on’s top experts in hematology and hematologic malignancies. Parti cipants will have the opportunity to interact with these thought leaders in several panel discussions.

This annual hematology review is one of the most comprehensive, educati onal hematology conferences in the country. Our excepti onal faculty will provide a concise and practi cal summary of the American Society of Hematology annual meeti ng, presenti ng the most current hematology research and clinical practi ce.

PLANNING COMMITTEERuemu Birhiray, MD (Chair)CEO, Indy Hematology Educati on Inc.Partner and Vice President,Hematology Oncology of Indiana, PC Michael C. Wiemann, MD (Co-Chair)Providence Hospital/St. John HealthSenior VP, CMO

Donna Birhiray, OTR, MBAIndy Hematology Educati on Inc.Treasurer

Jenny KronenbergRiverview HealthCredenti aling Specialist/CME Coordinator

Debbie LocklearMeeti ng Services UnlimitedPresident

Tina MachinaMeeti ng Services UnlimitedDirector of Conventi ons

REGISTRATIONRegister online at indyhematologyreview.com, click on Register.

Early bird registrati on ends February 22.Cost for full-day symposium:Early Bird Physicians $150Early Bird Physicians + CME/CNE Fee $170Early Bird Allied Health/Pharmacists $90Early Bird Allied Health/Pharmacists+ CME/CNE Fee $110Exhibitors and Vendors $300

Aft er February 22:Physicians $175Physicians + CME/CNE Fee $195Allied Health/Pharmacists $110Allied Health/Pharmacists + CME/CNE Fee $130Exhibitors and Vendors $300Scholarships* $25(Nurses, Residents, Students, Fellows)

*A limited number of scholarships is available on a fi rst-come, fi rst-served basis.

If you are registering for clinicians in your offi ce, ensure that you fi ll in the att endee’s name and e-mail in appropriate boxes so that the post-event survey and conti nuing educati on credits are e-mailed to the att endee.

REFUND POLICYThose who request a registrati on cancellati on refund on or before March 1, 2017 will receive a Full Refund. Aft er March 1, there will be NO REFUND.

HOTEL RESERVATIONSMake reservati ons online at indyhematologyreview.com or call the Indianapolis Marriott Downtown, 350 W. Maryland Street, Indianapolis, IN 46225 at 317-822-3500 or 1.800.MARRIOTT. Menti on “Indy Hematology Review” for the discounted group rate of $179 plus tax. The block of discounted rooms will be released on Tuesday, February 21, 2017.

PARKINGParking is available at the Indianapolis Marriott Downtown. Daily 24-hour parking rates are $40 for self-parking and $45 for valet. QUESTIONS?Please contact Erica Olivero, 317-713-1536,erica@conventi onmanagers.com.

Indy Hematology Review

c/o Meeti ng Services U

nlimited

135 S. Mitt hoeff er Rd.

Indianapolis, IN 46229

AGENDA7:00 AM – Registrati on

7:30 AM – Breakfast: Sponsored Satellite Symposium

8:30 AM – State of the Art of Hematology: Emerging TherapiesRuemu E. Birhiray, MD – ChairCEO, Indy Hematology Educati on Inc.Partner and Vice President, Hematology Oncology of Indiana, PC (Indianapolis, IN)

9:00 AM – Benign Hematology: Changing ParadigmsCraig Kessler, MDAtt ending Hematologist-OncologistMedstar Georgetown University HospitalProfessor of Medicine and PathologyDepartments of Medicine and PathologyGeorgetown University Medical Center (Washington, DC)

9:30 AM – Multi ple Myeloma: Immunotherapy and BeyondPaul Richardson, MDAssociate Professor of MedicineHarvard Medical SchoolDana-Farber Cancer Insti tute (Boston, MA)

10:00 AM – Waldenström’s Macroglobulinemia: How I treat; Emerging and current therapiesSteven Treon, MDAssociate Professor, Department of MedicineHarvard Medical SchoolDirector, Bing Center for Waldenström’s Macroglobulinemia, Adult OncologyDana-Farber Cancer Insti tute (Boston, MA)

10:30 AM – Break and Q & A

10:45 AM – Not so Benign Hematology: Complementopathies and Aplasti c AnemiaRobert Brodsky, MDDirector, Division of HematologyProfessor of Medicine and OncologyThe Johns Hopkins Family ProfessorJohns Hopkins Medicine (Balti more, MD)

11:15 AM – Aggressive B and T Cell Lymphomas: Treatment Paradigms in 2017John Leonard, MDAtt ending Physician, New York – Presbyterian HospitalRichard T. Silver Disti nguished Professor of Hematology and Medical OncologyWeill Cornell Medical College (New York, NY)

11:45 AM – T. HOWARD LEE KEYNOTE LECTUREFollicular Lymphoma: Targeted, Maintained, and Cured?Bruce Cheson, MDDeputy Chief, Division of Hematology and OncologyHead of Hematology and Professor of MedicineLombardi Comprehensive Cancer CenterGeorgetown University Hospital (Washington, DC)

12:30 PM – Q & A

12:45 PM – Lunch: Sponsored Satellite Symposium

1:45 PM – Challenging Cases Presentati onMichael C. Wiemann, MD – Co-ChairProvidence Hospital/St. John HealthSenior VP, CMO (Warren, MI)

1:50 PM – Myeloproliferati ve DisordersAyalew Teff eri, MDProfessor of Hematology and Internal MedicineMayo Clinic (Rochester, MN)

2:20 PM – Myelodysplasti c SyndromeCharles Schiff er, MDProfessor of Oncology and MedicineHead, Multi disciplinary Leukemia/Lymphoma TeamDirector, Fellowship Program, Division of Hematology/OncologyWayne State University School of Medicine (Detroit, MI)

2:50 PM – Chronic Lymphocyti c Leukemia: State of the ArtAdrian Wiestner, MD, PhDSenior Investi gator, Laboratory of Lymphoid MalignanciesNati onal Heart Lung and Blood Insti tute (Bethesda, MD)

3:20 PM – Chronic Myeloid Leukemia: Current and Emerging TherapiesRichard Larson, MDProfessor of MedicineDirector, Hematologic Malignancies Clinical Research ProgramUniversity of Chicago Medical Center (Chicago, IL)

3:50 PM – Break and Q & A

4:00 PM – Acute Lymphoblasti c Leukemia – Beyond AdolescenceRichard Stone, MDDirector, Adult Leukemia ProgramDana-Farber Cancer Insti tuteAtt ending Physician, Brigham and Women’s HospitalProfessor of Medicine, Harvard Medical School (Boston, MA)

4:30 PM – Acute Promylelocyti c and other Acute Myeloid Leukemia’s: The slaying of the old dragon?Marti n Tallman, MDChief, Leukemia ServiceMemorial Sloan-Kett ering Cancer CenterWeill Cornell Medical College (New York, NY)

5:00 PM – Hematopoieti c Stem Cell Transplantati on: When to off er and when to treat?Richard Childs, MDNati onal Insti tutes of Health (Bethesda, MD)

5:30 PM – The Best of ASH 2016Robert Brodsky, MD

5:50 PM – Q & A

6:00 PM – Wrap-Up: Closing Remarks

NURSING SYMPOSIUM AGENDA9:00 AM – LymphomaJohn Leonard, MD

9:30 AM – Acute LeukemiaRichard Stone, MD

10:00 AM – Hematopoieti c Stem Cell Transplantati onRichard Childs, MD

10:30 AM – Break

10:40 AM – MyelomaPaul Richardson, MD

11:10 AM – Survivorship: The Concept of HopeLinda Nielsen, DNP, APNHematology Oncology of Indiana (Indianapolis, IN)

11:40 AM – Adjourn and join for T. Howard Lee Lecture at 11:45 AMDisclosure informati on, biographies and slides(where authorized by the presenter) will be available

at indyhematologyreview.com

NURSING LEARNING OBJECTIVESAt the completi on of this acti vity parti cipants should be able to:

• Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocyti c and Myeloid Leukemia, and Myeloproliferati ve disorders.

• Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recogniti on.

• Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeti ng in San Diego, California in December 2016.

• Identi fy new regimens for Hematopoieti c Stem Cell transplantati on and identi fi cati on of transplant candidates.

• Review the advancement in benign hematology research.• Review new treatment regimens in follicular lymphoma.

PHARMACY LEARNING OBJECTIVESAt the completi on of this acti vity, the parti cipant should be able to:

• Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocyti c and Myeloid Leukemia, and Myeloproliferati ve disorders.

• Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recogniti on.

• Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeti ng in San Diego, California in December 2016.

• Identi fy new regimens for Hematopoieti c Stem Cell transplantati on and identi fi cati on of transplant candidates.

• Review the advancement in benign hematology research.• Review new treatment regimens in follicular lymphoma.

CONTINUING EDUCATION INFORMATIONPHYSICIANS AND PHYSICIAN ASSISTANTSCME LEARNING OBJECTIVESAt the completi on of this acti vity parti cipants should be able to:

• Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocyti c and Myeloid Leukemia, and Myeloproliferati ve disorders.

• Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recogniti on.

• Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeti ng in San Diego, California in December 2016.

• Identi fy new regimens for Hematopoieti c Stem Cell transplantati on and identi fi cati on of transplant candidates.

• Review the advancement in benign hematology research.• Review new treatment regimens in follicular lymphoma.

ACCREDITATION STATEMENTRiverview Hospital is accredited by the Indiana State Medical Associati on Conti nuing Medical Educati on to provide conti nuing medical educati on for physicians.

DESIGNATION STATEMENTRiverview Hospital designates this Live Acti vity for a maximum of 8 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their parti cipati on in the acti vity.

DISCLOSURE STATEMENTIn accordance with the Accreditati on Council for Conti nuing Medical Educati on (ACCME) Standards for Commercial Support, educati onal programs sponsored by Riverview Hospital must demonstrate balance, independence, objecti vity, and scienti fi c rigor. All faculty, authors, editors, and planning committ ee members parti cipati ng in a Riverview Hospital sponsored acti vity are required to disclose any relevant fi nancial interest or other relati onship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educati onal acti vity.

NOTEWhile off ering the CME credit hours above, this acti vity is not intended to provide extensive training in the fi eld.